法舒地尔对急性脑梗死患者血清hs-CRP和TNF-α的影响  

Changes of high-sensitive C-reactive protein and tumor necrosis factor-α of patients with acute cerebral infarction treated by Fasudi

作　　者：刘平[1] 

机构地区：[1]河南中医学院第一附属医院,河南郑州450000

出　　处：《山东医药》2008年第31期18-19,共2页Shandong Medical Journal

基　　金：河南省科技厅科技发展计划项目(0424410044)

摘　　要：目的探讨新型细胞内钙离子拮抗剂法舒第尔对急性脑梗死患者血清hs-CRP和TNF-α的影响及临床疗效。方法64例脑梗死患者随机分为观察组和对照组,在常规使用阿司匹林肠溶片基础上,观察组静脉滴注盐酸法舒地尔注射液,对照组静脉滴注奥扎格雷钠注射液,均治疗14 d;治疗前及治疗3个月后随访监测血清高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)水平,并根据临床神经功能缺损程度评分判定疗效。结果两组治疗后hs-CRP、TNF-α水平均较治疗前显著降低(P均<0.05);治疗后观察组hs-CRP、TNF-α水平明显低于对照组(P均<0.05)。观察组临床治疗总有效率显著高于对照组,差异有统计学意义(P<0.05)。结论新型细胞内钙离子拮抗剂法舒第尔对急性脑梗死具有良好的疗效。Objective To observe the effect of Fasudi injection which was neotype intracellular calciumion antagon on acute cerebral infarction. Methods 64 patients with acute cerebral infarction were divided randomly into control group and experimental group. In the base of aspirin used rout, Fasudil was used in patients of experimental group by intervenous drop infusion, while sodium ozagrel was used in patients of control group by intervenous drop infusion. Course of treatment of the two groups were 14 days. High-sensitive C-reactive protein（hs-CRP） and tumor necrosis factor-α（TNF-α） were tested , and curative effect were judge by clinical neurologic impairment score before and after 3-month treatment. Results hs- CRP and TNF-α levels of post-treatment were lower than those of prior treatment（ P 〈 0.05 ）. hs-CRP and TNF-α of post-treatment in the experimental group were lower than those in the control group （ P 〈 0. 05 ）. Clinical total effective rate in the experimental group was higher than that of control group（ P 〈 0. 05）. Conclusions Fasudi injection is effective medicine for treating acute cerebral infarction.

关 键 词：法舒地尔 脑梗死 急性 C反应蛋白质 高敏 肿瘤坏死因子 

分 类 号：R743.33[医药卫生—神经病学与精神病学]